Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder

Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder

PurposeFingolimod, an oral treatment for relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound in disease activity after therapy cessation. We described a patient with neuromyelitis optica spectrum disorder (NMOSD) who was previously diagnosed with RRMS and ex...

Full description

Bibliographic Details
Main Authors:	Wei Lin, Chung-Hsing Chou, Fu-Chi Yang, Chia-Kuang Tsai, Yu-Kai Lin, Yueh-Feng Sung
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Immunology
Subjects:	fingolimod withdrawal syndrome relapse-remitting multiple sclerosis neuromyelitis optica spectrum disorder fingolimod rebound syndrome aquaporin-4 antibody
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1115120/full

Similar Items

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
by: Brian Barry, et al.
Published: (2019-11-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing–Remitting Multiple Sclerosis
by: Claudia Fracasso, et al.
Published: (2022-06-01)

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
by: Abdoreza Naser Moghadasi, et al.
Published: (2020-07-01)

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
by: Valeria Koska, et al.
Published: (2021-10-01)

Fingolimod (FTY720) Tedavisinin Relapsing-Remitting Multipl Skleroz Hastalarında Karaciğer Enzim Düzeylerine Etkisi
by: Duygu Tap, et al.
Published: (2020-12-01)

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
by: Thomas Roux, et al.
Published: (2017-05-01)

Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Xin Wu, et al.
Published: (2021-05-01)

The developmental history of study on neuromyelitis optica
by: Kai FENG, et al.
Published: (2014-09-01)

Symptomatic narcolepsy as a presenting feature of neuromyelitis optica
by: Pradeep Kallollimath, et al.
Published: (2018-01-01)

Neuromyelitis optica - an update: 2007-2009
by: Jacob Anu
Published: (2009-01-01)

Prognosis of Relapsing Neuromyelitis Optica
by: J Gordon Millichap
Published: (2003-03-01)

Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder
by: Oliver Schmetzer, et al.
Published: (2021-03-01)

Neuromyelitis optica
by: Jacob Anu, et al.
Published: (2007-01-01)

CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS
by: Rizaldy Taslim Pinzon, et al.
Published: (2017-11-01)

IMMUNOLOGICAL PRECONDITIONS OF CONVERSION FROM NATALIZUMAB TO FINGOLIMOD
by: E. V. Popova, et al.
Published: (2017-12-01)

Clinical characteristics of late ⁃ onset and very late ⁃ onset neuromyelitis optica spectrum disorders
by: ZHANG Jing, et al.
Published: (2022-09-01)

Primary Sjögren's syndrome patients with neuromyelitis optica spectrum disorders: clinical analysis of 4 cases and review of the literature
by: Jing-jiong CHEN, et al.
Published: (2013-05-01)

Neuromyelitis Optica (NMO) — Study Review
by: Justyna Chojdak-Łukasiewicz
Published: (2021-06-01)

Neuromyelitis optica spectrum disorders in children
by: N. F. Akhmetgaleeva, et al.
Published: (2024-08-01)

Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience
by: Narayanan Unni, et al.
Published: (2013-01-01)

Consensus of expert advices on routing, diagnosis, and management of patients with neuromyelitis optica spectrum disorders
by: A. N. Boyko, et al.
Published: (2021-10-01)

Are different degrees of lymphopenia for FTY720 associated with serious infectious-type events? No
by: Catalina Márquez-Martín, et al.
Published: (2022-07-01)

Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder
by: Shin Ju Oh, et al.
Published: (2017-03-01)

Therapeutic efficacy of plasma exchange in neuromyelitis optica
by: Rajesh Kumar, et al.
Published: (2018-01-01)

Autoantibodies in patients with neuromyelitis optica
by: Xin FAN, et al.
Published: (2016-10-01)

Association Between Helicobacter Pylori Infection and Seronegative Neuromyelitis Optica Spectrum Disorder
by: Mahdi Barzegar, et al.
Published: (2023-01-01)

Intractable vomiting and hiccups as the presenting symptom of neuromyelitis optica
by: Girish Baburao Kulkarni, et al.
Published: (2014-01-01)

Research progress of neuromyelitis optica spectrum disorders: Chinese scholars' reports published abroad
by: Jie-xi WEN, et al.
Published: (2016-09-01)

Advances on the diagnosis and treatment of aquaporin 4 antibody positive neuromyelitis optica spectrum disorders
by: XU Hong-jia, et al.
Published: (2024-05-01)

Optical Coherence Tomography in Chronic Relapsing Inflammatory Optic Neuropathy, Neuromyelitis Optica and Multiple Sclerosis: A Comparative Study
by: Maziar Eslami, et al.
Published: (2022-08-01)

Cerebral Blood Flow Changes in Multiple Sclerosis and Neuromyelitis Optica and Their Correlations With Clinical Disability
by: Xue Zhang, et al.
Published: (2018-05-01)

Neuromyelitis optica spectrum disorder: a pediatric case report
by: Mujgan Arslan, et al.
Published: (2017-09-01)

A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
by: Mehrdokht Mazdeh, et al.
Published: (2019-04-01)

Clinical and brain MRI appearances in neuromyelitis optica
by: Shijuan ZHANG, et al.
Published: (2011-06-01)

Convergence spasm due to aquaporin-positive neuromyelitis optica spectrum disorder
by: Pınar Özçelik, et al.
Published: (2017-06-01)

The clinical characteristics of neuromyelitis optica spectrum disorders with other autoimmune diseases
by: SUN Qing⁃li, et al.
Published: (2022-04-01)

Clinical and imaging characteristics and autoantibody analysis of neuromyelitis optica spectrum disorders
by: Nan LIU, et al.
Published: (2014-09-01)

Toxicidad hepática por fingolimod
by: juan sebastian theran leon, et al.
Published: (2024-02-01)

Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic
by: Brandon Brown, et al.
Published: (2019-11-01)